A proven partner for
your biosimilar
strategy
BENEFITS FOR ALL
Our manufacturer- and pharmacy-agnostic approach gives members an independent advocate for both the clinical and cost considerations of biosimilar therapies.
Aligned 100% to your biosimilar strategy, member communications clearly and consistently guide patients to the lowest-net-cost therapies.
With clarity on cost, copay assistance, clinical evidence and site-of-care recommendations, providers can focus on treating your members with optimal therapies and efficiency.
HEAR FROM THE EXPERTS
BIOSIMILAR WEBINAR
WHAT TO WATCH FOR IN 2023
HUMIRA® AND THE LOOMING BIOSIMILAR BOOM
HUMIRA BIOSIMILARS SCHEDULE
150+
Nationwide
1:1
member access to dedicated support from RxSS specialty pharmacy team
Insights
from monthly reporting on
trends, spending, realized
savings and opportunities
COMPREHENSIVE BY DESIGN
Every approved biosimilar is mapped with its reference product and relevant off-label indications to ensure every suggestion is in sync with your plan design strategy.
One-on-one interaction with a Certified Specialty Pharmacist (CSP) informs members on efficacy, side effects and evidence-based biosimilar outcomes.
Provider outreach and interaction on plan design preference, biosimilar interchangeability status, and pricing considerations is also conducted by a CSP.
Site-of-care options are evaluated to ensure that biosimilar therapies are dispensed or infused at the lowest net cost for the member and plan.
BEFORE AND AFTER
